Toceranib phosphate resolves right heart obstruction secondary to a heart base neoplasm in a dog.
Canine
Chemodectoma
Congestive heart failure
Ectopic thyroid carcinoma
Neuroendocrine tumour
Journal
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology
ISSN: 1875-0834
Titre abrégé: J Vet Cardiol
Pays: Netherlands
ID NLM: 101163270
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
11
03
2022
revised:
20
09
2022
accepted:
26
09
2022
pubmed:
11
11
2022
medline:
21
12
2022
entrez:
10
11
2022
Statut:
ppublish
Résumé
An eight-year-old castrated male, 45 kg labrador retriever presented for evaluation of a two-week history of cough and tachypnoea. Echocardiography revealed an approximately 10 cm heart base mass, which extended to the right atrioventricular junction, causing compression of both the right atrium and ventricle resulting in right-sided congestive heart failure (abdominal effusion). Cytology of the mass was consistent with a neuroendocrine carcinoma. Given the location and description, a chemodectoma or ectopic thyroid carcinoma was suspected. The patient was treated with toceranib phosphate and famotidine. At the follow-up appointment four weeks later, the right heart compression had resolved due to a clinically significant reduction in the size of the mass. The patient was prescribed furosemide and enalapril to treat right-sided congestive heart failure. When considering treatment options for haemodynamically significant heart base masses, treatment with toceranib phosphate may result in rapid clinical benefit.
Identifiants
pubmed: 36356366
pii: S1760-2734(22)00095-9
doi: 10.1016/j.jvc.2022.09.003
pii:
doi:
Substances chimiques
toceranib phosphate
24F9PF7J3R
Pyrroles
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
38-42Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interest Statement The authors declare no conflict of interest.